Pimavanserin

Edit

ACADIA Pharmaceuticals Reports Third Quarter 2013 Financial Results

07 Nov 2013

“We remain focused on building value in our pimavanserin franchise and advancing our pipeline,” said Uli Hacksell, Ph.D., ACADIA’s Chief Executive Officer. “During the third quarter of 2013, we continued to build on the strong momentum established in the first half of the year and made important progress in advancing our Parkinson’s disease psychosis program with pimavanserin toward registration....(size: 34.4Kb)

Edit

ACADIA Pharmaceuticals Reports Third Quarter 2013 Financial Results (ACADIA Pharmaceuticals Inc)

noodls

06 Nov 2013

"We remain focused on building value in our pimavanserin franchise and advancing our pipeline," said Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer. "During the third quarter of 2013, we continued to build on the strong momentum established in the first half of the year and made important progress in advancing our Parkinson's disease psychosis program with pimavanserin toward registration....(size: 9.3Kb)

Edit

Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals, ViroPharma, and MannKind

PR Newswire

06 Nov 2013

(ACADIA) announced the publication of data from its pivotal Phase III -020 Study with pimavanserin in patients with Parkinson's disease psychosis (PDP) in the November 1, 2013 online issue of The Lancet. The Company informed that in the -020 Study, pimavanserin demonstrated significant and clinically meaningful benefits and was safe and well tolerated in patients with PDP....(size: 8.8Kb)

Edit

ACADIA Pharmaceuticals Announces Publication in The Lancet of Pivotal Phase III Parkinson’s Disease Psychosis Trial with Pimavanserin

Business Wire

01 Nov 2013

These statements include but are not limited to statements related to the progress and timing of ACADIA’s drug discovery and development programs, either alone or with a partner, including clinical trials, the benefits to be derived from ACADIA’s product candidates, in each case including pimavanserin, the potential for pimavanserin to be approved ......(size: 11.8Kb)

Edit

ACADIA Pharmaceuticals Announces Publication in The Lancet of Pivotal Phase III Parkinson’s Disease Psychosis Trial with Pimavanserin (ACADIA Pharmaceuticals Inc)

noodls

01 Nov 2013

These statements include but are not limited to statements related to the progress and timing of ACADIA's drug discovery and development programs, either alone or with a partner, including clinical trials, the benefits to be derived from ACADIA's product candidates, in each case including pimavanserin, the potential for pimavanserin to be approved ......(size: 10.3Kb)

Edit

ACADIA Pharmaceuticals Announces Publication in The Lancet of Pivotal Phase III Parkinson's Disease Psychosis Trial ...

Stockhouse

01 Nov 2013

These statements include but are not limited to statements related to the progress and timing of ACADIA’s drug discovery and development programs, either alone or with a partner, including clinical trials, the benefits to be derived from ACADIA’s product candidates, in each case including pimavanserin, the potential for pimavanserin ......(size: 9.8Kb)

Edit

New drug for Parkinson's shows promise (University of London)

noodls

01 Nov 2013

Pimavanserin, a new non-dopaminergic drug, may offer the first safe and effective treatment for these psychotic symptoms, according to a phase 3 randomised trial led by scientists from King's College London, published in The Lancet ... Participants were randomly assigned to receive 40mg of pimavanserin orally once daily or matching placebo for 6 weeks ... No worsening of motor symptoms was reported in patients given pimavanserin....(size: 5.0Kb)

Edit

New drug may provide first safe, effective treatment for psychotic symptoms

Fox News

01 Nov 2013

Known as pimavanserin, the drug works by blocking serotonin 5-HT2A receptors in the neocortex, which had been previously associated with visual hallucinations ... The researchers chose to analyze the drug pimavanserin, because it only targeted the 5HT system ... Each participant was randomly assigned 40 milligrams of pimavanserin to take orally each day or a matching placebo to take each day for six weeks....(size: 4.3Kb)

Edit

ACADIA Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 6, 2013

Business Wire

30 Oct 2013

ACADIA has a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis ... programs, either alone or with a partner, including clinical trials, and the benefits to be derived from ACADIA’s product candidates, in each case including pimavanserin....(size: 5.4Kb)

Edit

ACADIA Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 6, 2013 (ACADIA Pharmaceuticals Inc)

noodls

30 Oct 2013

ACADIA has a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis ... programs, either alone or with a partner, including clinical trials, and the benefits to be derived from ACADIA's product candidates, in each case including pimavanserin....(size: 4.4Kb)

Edit

Acadia Pharma jumps 13 percent

U~T San Diego

24 Oct 2013

However, Acadia shares plunged 15 percent Oct. 9, and 15.5 percent Oct ... Acadia's flagship drug, pimavanserin, treats Parkinson's disease psychosis. Pimavanserin is in Phase 3 trials, and results so far have been positive ... However, pimavanserin treats the psychological symptoms that affect some patients, such as hallucinations and delusions ... ....(size: 1.5Kb)

Edit

Pimavanserin: The Most Underestimated Blockbuster In Biotechnology

Seeking Alpha

14 Oct 2013

Additional disclosure ... ....(size: 0.2Kb)

Edit

SHARES OF S.D.-BASED ACADIA DOWN

U~T San Diego

09 Oct 2013

Shares of Acadia Pharmaceuticals dropped as much as 19 percent Tuesday. There was no news from the company to account for the drop ... conference Tuesday was “bearish” on the drug, pimavanserin ... Bradley J ... ....(size: 0.9Kb)

Make changes yourself !

ACADIA Pharmaceuticals (ACAD) 4Q - FY2010 Financial Results - CRWEnewswire Stock Highlight